Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
CVAC were in the spotlight as the companies restructured their existing collaboration agreement into a new licensing agreement. Recap of the Week's Most Important Stories GSK, CVAC Restructure Agreement : GSK and CureVac announced a restructuring of their existing collaboration into a new licensing agreement. Both companies collaborated in 2020 to develop mRNA vaccines for infectious diseases. GSK and CVAC currently have vaccine candidates for seasonal influenza and COVID-19 in phase II, and avian influenza in phase I development. Per the terms of the new agreement, GSK will assume full control of developing and manufacturing mRNA candidate vaccines for influenza and COVID-19, along with commercialization rights. Meanwhile, CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range. CVAC also retains exclusive rights to the additional undi
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the FirmGlobeNewswire
- MRNA Deadline: MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud LawsuitPR Newswire
- The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Moderna, Inc. Accesswire
- Faruqi & Faruqi Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNAPR Newswire
- IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNAGlobeNewswire
MRNA
Earnings
- 8/1/24 - Beat
MRNA
Sec Filings
- 10/4/24 - Form 4
- 10/4/24 - Form 3
- 10/2/24 - Form 8-K
- MRNA's page on the SEC website